Nurix Therapeutics, Inc.
NRIX
$15.96
-$0.32-1.97%
NASDAQ
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -53.95% | 71.99% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -53.95% | 71.99% | |||
| Cost of Revenue | 1.34% | -3.59% | |||
| Gross Profit | -12.15% | 11.22% | |||
| SG&A Expenses | 7.05% | 3.72% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.15% | -2.63% | |||
| Operating Income | -11.31% | 9.07% | |||
| Income Before Tax | -11.45% | 9.49% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.45% | 9.49% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.45% | 9.49% | |||
| EBIT | -11.31% | 9.07% | |||
| EBITDA | -10.69% | 8.71% | |||
| EPS Basic | 3.72% | 19.89% | |||
| Normalized Basic EPS | 3.72% | 19.90% | |||
| EPS Diluted | 3.72% | 19.89% | |||
| Normalized Diluted EPS | 3.72% | 19.90% | |||
| Average Basic Shares Outstanding | 15.76% | 12.99% | |||
| Average Diluted Shares Outstanding | 15.76% | 12.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||